Skip to main content
. 2005 Dec 2;8(1):R12. doi: 10.1186/ar1861

Figure 3.

Figure 3

Two pharmacokinetic patterns after single subcutaneous injections of PEG-uricase. (a) 'Long-circulating' group: eight subjects with uricase activity present in plasma at 21 days after injection. (b) 'Early elimination' group: five subjects with undetectable plasma uricase activity beyond 10 days after injection. The keys indicate the dose of PEG-modified recombinant mammalian urate oxidase (PEG-uricase).